Stock Events

Stock Events

Ascendis Pharma A/S 

€226.00
59
+€2.00+0.89%Friday 07:02

Statistics

Day High
226
Day Low
226
52W High
226
52W Low
195
Volume
-
Avg. Volume
-
Mkt Cap
14.87B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 11Expected
Q2 2026
Next
0.8
1.47
2.13
2.8
Expected EPS
0.79755651375348
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow A710.F. It's not an investment recommendation.
NVIDIA
13
NVDA
Microsoft
12
MSFT
Apple
8
AAPL
Meta Platforms
8
META

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap158.45B
Pfizer competes in various therapeutic areas including those targeted by Ascendis Pharma's endocrinology and oncology pipeline.
Novo Nordisk
NVO
Mkt Cap164.79B
Novo Nordisk is a leader in diabetes and growth disorders, directly competing with Ascendis Pharma's growth hormone deficiency treatments.
Lilly(Eli) &
LLY
Mkt Cap1.02T
Eli Lilly has a strong presence in endocrinology, particularly in growth hormone and diabetes treatments, competing with Ascendis' portfolio.
Vertex Pharmaceuticals
VRTX
Mkt Cap127.93B
Vertex Pharmaceuticals competes in the development of treatments for genetic disorders, a key area of focus for Ascendis Pharma.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.07B
BioMarin Pharmaceutical focuses on rare diseases, including areas like growth disorders, directly competing with Ascendis' therapies.
Opko Health
OPK
Mkt Cap1.16B
OPKO Health has a division focused on pharmaceuticals, including growth hormone treatments, making it a direct competitor.
Ligand Pharmaceuticals
LGND
Mkt Cap6.04B
Ligand Pharmaceuticals' technology platforms and partnerships enable it to compete in the development of endocrinology and oncology drugs.
Regeneron Pharmaceuticals
REGN
Mkt Cap75.69B
Regeneron Pharmaceuticals competes in the biopharmaceutical space with a focus on innovative treatments, overlapping with Ascendis' therapeutic areas.
Biogen
BIIB
Mkt Cap32.49B
Biogen focuses on neurological and neurodegenerative diseases but its expansion into other biopharmaceutical areas can position it as a competitor.
AMGEN
AMGN
Mkt Cap217.9B
Amgen's broad focus on biotechnology treatments for various diseases, including bone health and oncology, places it in competition with Ascendis Pharma.

About

Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
Show More
CEO
Employees
1189
Country
Denmark
ISIN
DK0060615755
WKN
000A42ANJ

Listings

SA
BR
A1SN34.SA
MX
MX
ASND1N.MX
STU
DE
A71.STU
MU
DE
A710.MU

0 Comments

Share your thoughts

FAQs

What is Ascendis Pharma A/S stock price today?▼
The current price of A710.F is €226.00 EUR — it has increased by +0.89% in the past 24 hours. Watch Ascendis Pharma A/S stock price performance more closely on the chart.
What is Ascendis Pharma A/S stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Frankfurt Exchange exchange Ascendis Pharma A/S stocks are traded under the ticker A710.F.
What is Ascendis Pharma A/S market cap?▼
Today Ascendis Pharma A/S has the market capitalization of 14.87B
When is the next Ascendis Pharma A/S earnings date?▼
Ascendis Pharma A/S is going to release the next earnings report on November 11, 2026.
What were Ascendis Pharma A/S earnings last quarter?▼
A710.F earnings for the last quarter are 2.8 EUR per share, whereas the estimation was 1.48 EUR resulting in a +89.09% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Ascendis Pharma A/S have?▼
As of October 31, 2026, the company has 1,189 employees.
In which sector is Ascendis Pharma A/S located?▼
Ascendis Pharma A/S operates in the Other sector.
When did Ascendis Pharma A/S complete a stock split?▼
Ascendis Pharma A/S has not had any recent stock splits.